FACT Cellular Therapy & CAR-T Accreditation — Frequently Asked Questions

What is FACT accreditation for cellular therapy and CAR-T programs?

FACT accreditation is a peer-reviewed quality standard administered by the Foundation for the Accreditation of Cellular Therapy (FACT) — a nonprofit set up in 1995 and affiliated with two professional societies, ISCT and ASTCT (FACT, The FACT Story, page opened October 3, 2026). FACT verifies that a clinical program meets evidence-based standards for the collection, processing, and administration of cellular therapy products across four program types: Hematopoietic Cellular Therapy (HCT), Immune Effector Cells (IEC/CAR-T), Cord Blood Banking, and Collection for Further Manufacturing.

FACT's list of accredited organizations showed 302 organizations in its Cellular Therapy category and 50 in its Cord Blood category on October 4, 2026. Filtered by clinical service, 204 organizations listed immune effector cellular therapy (FACT, accredited organizations, page opened October 4, 2026). The global cell and gene therapy market: $8.94 billion (2025), projected $45.24 billion by 2035 at 17.60% CAGR.

Do CAR-T manufacturers require FACT accreditation to access their products?

Yes, in practice. The major commercial CAR-T manufacturers require or strongly recommend FACT IEC accreditation:

• Novartis / Kymriah — requires authorized treatment center status, which requires FACT IEC accreditation
• Kite-Gilead / Yescarta — requires authorized treatment center qualification including FACT accreditation
• Bristol Myers Squibb / Breyanzi — requires certified treatment center status
• Janssen / Carvykti — requires authorized treatment center certification

Without FACT IEC accreditation, hospitals cannot order or administer these products — each priced at $375,000 to $450,000+ per infusion. The access barrier is contractual, not regulatory: manufacturers impose it as a condition of product distribution agreements.

Does Medicare require FACT accreditation for CAR-T therapy reimbursement?

Not under its national coverage determination for CAR-T (NCD 110.24), which does not name FACT. The NCD covers autologous CAR-T for a medically accepted indication when the therapy is given at a facility enrolled in the FDA REMS. FDA eliminated the REMS for the six autologous CAR-T products in June 2025, and the NCD on CMS's site, last reviewed in August 2019, still states the REMS condition (CMS, NCD 110.24, Chimeric Antigen Receptor (CAR) T-cell Therapy, page opened October 4, 2026). Manufacturer requirements and Blue Distinction are separate questions, covered in the answers above and below.

Blue Cross Blue Shield Blue Distinction Center for Transplants requires full FACT accreditation including IEC Standards compliance. Loss of Blue Distinction affects payer network access and reimbursement rates for the full transplant and cellular therapy service line.

What is the difference between FACT HCT accreditation and FACT IEC (CAR-T) accreditation?

FACT HCT (Hematopoietic Cellular Therapy) covers traditional bone marrow and peripheral blood stem cell transplantation. FACT IEC (Immune Effector Cells) covers programs administering FDA-approved CAR-T therapies. The standards are separate — different documents, different Crosswalk requirements, different minimum volume thresholds, different inspection criteria.

Academic transplant centers typically hold both. Community oncology programs typically pursue IEC only, entering cellular therapy through CAR-T rather than traditional transplantation. The minimum volume requirements differ by accreditation type; IHS assesses eligibility at engagement inception for each program type.

What is the FACT accreditation process and how long does it take?

Initial FACT accreditation takes 12 to 24 months. The phases:

1. Eligibility and Registration (Month 1) — confirm minimum volume requirements; sign BAA; pay registration fee
2. Compliance Crosswalk and document development (Months 1–12) — SOP library, QMP, Facility Grids, personnel documentation, Written Agreements, IT validation documentation
3. Desk review and RFI management (Months 12–14) — FACT Coordinator reviews uploaded documentation; IHS manages all RFI responses
4. On-site inspection (Months 14–18) — volunteer peer inspectors audit chain-of-custody, observe procedures, interview staff, evaluate facilities
5. CAPA response and accreditation award (Months 18–24) — IHS authors CAPA responses; accreditation granted upon FACT Committee acceptance

Annual Report required at Year 1 anniversary. Renewal report due 14 months before 3-year expiration.

What are the most common deficiencies found during FACT inspections?

The eight most consistently cited FACT deficiency areas:

1. Traceability / Chain of Custody — broken documentation chain from collection through manufacturing through administration
2. Written Agreements with manufacturers — missing or inadequately reviewed agreements with commercial CAR-T manufacturers
3. QMP execution — Quality Management Plan written but never executed; no management reviews, no quality indicators tracked, no corrective action
4. Adverse event reporting — inadequate CRS and neurotoxicity event reporting systems within mandated timeframes
5. SOP discrepancies — staff using procedures that differ from published SOPs
6. Training and competency assessments — missing documented annual competency assessments for all clinical and laboratory staff
7. ISBT 128 labeling — incomplete implementation. The 9th Edition recommends standardized labeling for further manufacturing products.
8. Electronic systems validation — EMR and LIMS not formally validated (IQ/OQ/PQ) prior to use

What is the difference between FACT and AABB accreditation for cellular therapy?

FACT and AABB have different scopes, inspection models, and cycle lengths:

For programs administering commercial CAR-T therapies, FACT is required. AABB standards compliance is required for blood bank operations that support cellular therapy programs. IHS advises on the combined FACT + AABB compliance framework for programs needing both.

Can a community cancer center get FACT accredited for CAR-T?

Yes. FACT's Community IEC Standards provide a fit-for-purpose accreditation pathway specifically designed for community oncology settings. The standards recognize operational differences between academic transplant centers and community cancer programs while maintaining equivalent patient safety requirements.

As CAR-T moves to second-line standard of care, community hospitals must build FACT programs from scratch. The demand is real and growing — hundreds of community oncology networks will need FACT Community IEC accreditation as CAR-T becomes standard rather than salvage therapy. IHS specializes in community CAR-T program development: clinical protocol documentation, nursing competency programs, FACT Crosswalk for Community IEC standards, and written agreements with commercial manufacturers.

How long is FACT accreditation valid before renewal?

FACT accreditation is valid for 3 years. Key milestones:

• Year 1 anniversary — Comprehensive Annual Report due: clinical outcomes, personnel changes, continued compliance evidence
• Before the end of the 3-year cycle — Full renewal report must be submitted to initiate re-inspection
• Year 3 — Full on-site re-inspection; accreditation renewed for another 3-year cycle

The 14-month renewal submission deadline is the most commonly missed milestone. IHS tracks cycle milestones for all active clients and initiates renewal preparation at Month 22, not Month 34.

What quality management system requirements does FACT require?

FACT requires a documented and executed Quality Management Plan (QMP) covering:

• Quality philosophy and organizational structure
• Management review protocols — documented reviews at defined intervals with quality data analysis
• Audit schedules — internal quality audits of all program components
• Quality indicators — tracked metrics with defined thresholds and corrective action triggers
• CAPA system — documented corrective and preventive actions for all quality findings
• Document control — version control, SOP review cycles, obsolete document management
• Adverse event reporting — defined systems for recognizing, investigating, and reporting CRS and neurotoxicity events

The QMP must be executed — FACT inspectors verify execution through documented management review records and evidence of corrective actions taken in response to quality data. Writing a QMP without executing it is the most common FACT citation.

What is a FACT Compliance Crosswalk and how is it built?

A FACT Compliance Crosswalk is a systematic mapping of every FACT standard to the program's internal policies, SOPs, and quality documents that demonstrate compliance. It is the central document FACT reviews before scheduling an on-site inspection. Building a complete Crosswalk for a CAR-T IEC program spans six facility components: Clinical Facility, Collection Facility (apheresis), Cell Processing Laboratory, Quality Management, Information Technology, and Personnel.

IHS builds the Crosswalk as the core deliverable of every FACT engagement — starting at engagement inception and managing it as a living document through desk review, RFI responses, and inspection. The Crosswalk methodology IHS uses is identical to the AccreditNet document management approach developed for URAC accreditation — adapted to FACT's standards architecture.

What changed in the FACT-JACIE 9th Edition Standards (effective February 2026)?

The FACT-JACIE 9th Edition (effective February 2, 2026) made three major changes from the 8th Edition:

1. Consolidated Collection Standards — peripheral blood, bone marrow, and TIL collection standards merged into a single Collection section with unified chain-of-custody requirements. Programs collecting multiple modalities must update their SOP libraries to the consolidated framework.
2. REMS-Based Standards Revised — FDA announced on June 27, 2025 that it had eliminated the REMS for the six autologous CAR-T products that were under a REMS (FDA, FDA Eliminates REMS for Autologous CAR T Cell Immunotherapies, page opened October 3, 2026). The Ninth Edition HCT Standards dropped or revised the Clinical Program standards that had followed those REMS, and FACT's change summary names patient wallet cards as one requirement no longer in the standards (FACT, Summary of Changes, Ninth Edition HCT Standards, page opened October 3, 2026).
3. ISBT 128 Labeling for Further Manufacturing — in its Summary of Changes, FACT lists two new recommendations for collections that go on to further manufacturing: one on product labeling and one on assigning an ISBT 128 Chain of Identity Identifier (FACT, Summary of Changes, Ninth Edition HCT Standards, page opened October 3, 2026).

All surveys after February 2, 2026 reference the 9th Edition. AABB separately updated its Cellular Therapy Services standards to the 12th Edition, effective July 1, 2025.

Does the FDA REMS program still apply to CAR-T therapies?

Not for the six autologous CAR-T products that were under a REMS. On June 27, 2025, FDA announced it had eliminated the REMS for Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. That ended the requirement that hospitals and clinics dispensing these products be specially certified and keep tocilizumab on site. FDA said the risk information can be conveyed adequately through the current product labeling, which includes a boxed warning, and the medication guides (FDA, FDA Eliminates REMS for Autologous CAR T Cell Immunotherapies, page opened October 3, 2026). FACT then dropped or revised the Clinical Program standards in its Ninth Edition HCT standards that had followed the REMS (FACT, Summary of Changes, Ninth Edition HCT Standards, page opened October 3, 2026). IHS helps programs bring their FACT Crosswalk and procedures in line with the current standards.

How does Blue Cross Blue Shield use FACT accreditation for CAR-T reimbursement?

Blue Cross Blue Shield Blue Distinction Center for Transplants requires full FACT accreditation — both HCT Standards compliance and IEC Standards compliance — for Blue Distinction Center designation. Blue Distinction Center designation affects: payer network tier placement, reimbursement rates for transplant and CAR-T services, patient steerage from BCBS plans to Blue Distinction Centers, and institutional revenue from BCBS-insured patients. Programs that lose Blue Distinction Center status face reimbursement rate changes and potential patient volume loss from BCBS plans. FACT IEC accreditation is a direct prerequisite for maintaining Blue Distinction Center for Transplants status.

What internal staff resources are needed to pursue and maintain FACT accreditation?

FACT requires:

• Quality Manager — can be fractional for smaller programs; manages QMP execution, tracks quality indicators, coordinates audits
• Medical Director — ultimate clinical accountability for all FACT standards; must be actively engaged in collegial review and QMP oversight
• Cell Processing Laboratory Director — responsible for processing facility compliance, equipment validation, and laboratory quality documentation

Programs performing approximately 70 cellular transplants per year require approximately 1.5 dedicated FTEs in the cell processing laboratory for quality and operational management. IHS minimizes the burden on internal staff by handling Crosswalk development, SOP drafting, mock inspection preparation, and annual report management.

How much does FACT accreditation consulting cost?

Engagements are scoped to each client's specific situation. IHS begins every engagement with a complimentary discovery call that produces a fixed-fee proposal tailored to your organization's size and timeline. Targeted engagements are scoped separately:

• 9th Edition transition gap analysis and Crosswalk update — scoped based on existing documentation maturity
• Mock inspection only — scoped based on program size and facility count
• Annual report support — scoped based on program complexity

FACT's own accreditation fees are not publicly disclosed — contact FACT directly for current fee information. Contact IHS for a tailored proposal.

Is the eighth edition of the FACT-JACIE standards still current?

On FACT's standards page, the FACT-JACIE hematopoietic cellular therapy standards appear as the Ninth Edition, with documents that include a summary of changes and a self assessment tool. The page lists no eighth edition for that set. The only Eighth Edition on the page, Version 8.2, belongs to the separate NetCord-FACT cord blood standards (FACT, Standards, page opened October 3, 2026). Ask FACT which edition applies on your inspection date.

Does FACT accredit programs outside the United States?

Yes. FACT's list of accredited organizations has a country filter, and on October 3, 2026 it offered 29 entries, including Canada, Saudi Arabia, the United Kingdom and the United States (FACT, accredited organizations, page opened October 3, 2026). Each listing shows the country, the FACT standards that apply and the services covered.